Skip to content

Study · Case report or series · n = 1 · 2003

1 result

Cyclical Cushing's syndrome in a patient with a bronchial neuroendocrine tumor (typical carcinoid) expressing ghrelin and growth hormone secretagogue receptors.

Arnaldi G, Mancini T, Kola B, Appolloni G, Freddi S, Concettoni C, Bearzi I, Masini A, Boscaro M, Mantero F

The Journal of clinical endocrinology and metabolism1 Dec 2003Cited by 43 (Europe PMC)

PMID14671177 (opens in a new tab)DOI10.1210/jc.2003-030514 (opens in a new tab)PepBankPUB-14671177
Publisher pagePubMedAsk about this study
Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

1 result from studies that gave the peptide. 1 result from people.

  1. 01HumanCase report or seriesEfficacy outcome

    In a woman with a cyclical ectopic ACTH-secreting bronchial carcinoid, hexarelin produced an in vivo ACTH hyperresponse.

    In plain wordsIn one woman with an ACTH-producing lung tumour, hexarelin caused an unusually strong ACTH rise.

    Peptide
    Hexarelin
    Outcome
    IncreaseACTH response to hexarelin in a patient with an ACTH-secreting bronchial carcinoid
    Study

    n = 1

    Outcome group
    Pituitary hormones · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    This finding correlates with the in vivo ACTH hyperresponsiveness to hexarelin (a GHS).
    2 context sentences
    Summary · context
    This is the first report of a cyclical ectopic ACTH-secreting tumor with an in vivo ACTH response to hexarelin coupled with the tumoral expression of ghrelin and GHS receptors.
    Summary · context
    A 56-yr-old woman was referred with a diagnosis of Cushing's disease.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.